Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc (NY: NUVB )

2.410 -0.060 (-2.43%)
Streaming Delayed Price Updated: 3:42 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,281,301
Open 2.490
Bid (Size) 2.410 (81)
Ask (Size) 2.420 (80)
Prev. Close 2.470
Today's Range 2.380 - 2.490
52wk Range 0.9500 - 4.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
From Nuvation Bio Inc.
Via Business Wire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
+53.50%
+53.50%
1 Month
-21.75%
-21.75%
3 Month
-20.72%
-20.72%
6 Month
-33.79%
-33.79%
1 Year
+72.14%
+72.14%

More News

Read More
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Via Benzinga
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
From Nuvation Bio Inc.
Via Business Wire
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024
Via InvestorPlace
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
From Nuvation Bio Inc.
Via Business Wire
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Via Benzinga
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Via Talk Markets
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
From Nuvation Bio Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.